Fundraising FoxNeoVac
1 known investors
Find your way into NeoVac
Sign up to see every warm intro you have to NeoVac
- Paths you didn't know you had: your email and LinkedIn already hold routes to the NeoVac team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
NeoVac develops proprietary lipid technology for lipid nanoparticles (LNPs) designed to support mRNA-based therapeutics in vaccines, cancer immunotherapy, and autoimmune disease treatment. The company's lipid platform emphasizes tunable degradability to enhance safety and efficacy profiles.
Founders & leadership
Board
DP
Dan PeerChairperson
AH
Adrian HillChairperson of the Scientific Advisory Board
Investors · 1
Future Planet Capitallisted by Future Planet CapitalLondon
How we know: Future Planet Capital's portfolio page · the VCSheet dataset · Not right? Tell us
Companies House · registry record
View on Companies House ↗- Registered name
- NEOVAC LTD
- Company number
- 13606487
- Status
- Active
- Company type
- Private limited company
- Incorporated
- 7 Sept 2021
- Registered office
- Suites 1 And 2 127 Olympic Avenue, Milton Park, Abingdon, OX14 4SA
- Nature of business (SIC)
- 72110 — Research and experimental development on biotechnology
- Accounts
- last made up to 31 Dec 2024 · next due 30 Sept 2026
- Confirmation statement
- last made up to 30 Mar 2026 · next due 13 Apr 2027
Current officers · 10
- Tova Sharon — secretary, appointed 2 Dec 2021
- Eran Eilat — director, appointed 7 Sept 2021
- Halil Emecen — director, appointed 7 Sept 2021
- Heinrich Haas — director, appointed 19 Aug 2025
- Douglas Hansen-Luke — director, appointed 7 Sept 2021
- Adrian Hill — director, appointed 7 Sept 2021
- Suzana Nahum Zilberberg — director, appointed 13 Jan 2023
- Dan Peer — director, appointed 7 Sept 2021
- Martin Wodak — director, appointed 10 Apr 2024
- Aleš Štrancar — director, appointed 28 Jan 2026
Source: Companies House public register · retrieved 23 Aug 2026. Contains public sector information licensed under the Open Government Licence v3.0.
Frequently asked questions
- What does NeoVac do?
- NeoVac develops proprietary lipid technology for lipid nanoparticles (LNPs) designed to support mRNA-based therapeutics in vaccines, cancer immunotherapy, and autoimmune disease treatment. The company's lipid platform emphasizes tunable degradability to enhance safety and efficacy profiles.
- Who are NeoVac's investors?
- NeoVac's investors include Future Planet Capital.